TreeFrog Therapeutics: Funding, Investors & Team (Sep 2026)
TreeFrog Therapeutics, a biotech company based in France, is working to make cell therapies accessible to a large number of patients. The company is using its proprietary C-Stem technology to develop a range of therapeutic options, allowing for the large-scale production of induced pluripotent stem cells and their conversion into high-quality microtissues ready for transplantation. With a team of experts and $82M raised in funding in 2021, TreeFrog Therapeutics is focused on advancing its stem cell-based therapies, with a particular focus on Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to promote the use of C-Stem and collaborate with key players in the cell therapy field.
TreeFrog Therapeutics has raised $110M across 3 funding rounds on record, the most recent an undisclosed round of $34.2M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TreeFrog Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
TreeFrog Therapeutics Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
TreeFrog Therapeutics raised $75.6M in a Series B announced in Sep 2021.
3.4 years later, an undisclosed round was announced in Feb 2025 with no disclosed amount.
3 months later, an undisclosed round of $34.2M was announced in May 2025.
TreeFrog Therapeutics Founders and Leadership Team
Contact details for the TreeFrog Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →TreeFrog Therapeutics Funding Compared to Other Biotechnology Startups
TreeFrog Therapeutics' latest round of $34.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TreeFrog Therapeutics in Biotechnology and Bordeaux
Companies Similar to TreeFrog Therapeutics
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
TreeFrog Therapeutics Funding FAQs
What does TreeFrog Therapeutics do?
TreeFrog Therapeutics, a biotech company based in France, is working to make cell therapies accessible to a large number of patients. The company is using its proprietary C-Stem technology to develop a range of therapeutic options, allowing for the large-scale production of induced pluripotent stem cells and their conversion into high-quality microtissues ready for transplantation. With a team of experts and $82M raised in funding in 2021, TreeFrog Therapeutics is focused on advancing its stem cell-based therapies, with a particular focus on Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to promote the use of C-Stem and collaborate with key players in the cell therapy field.
How much funding has TreeFrog Therapeutics raised?
TreeFrog Therapeutics has raised $110M across 3 rounds on record. The most recent is an undisclosed round of $34.2M announced in May 2025.
When did TreeFrog Therapeutics last raise funding?
TreeFrog Therapeutics' most recent funding round on record is an undisclosed round of $34.2M, announced in May 2025.
Who founded TreeFrog Therapeutics?
FundedIQ lists Erwan Bezard (Founder), Kevin Alessandri (Founder) at TreeFrog Therapeutics.
Where is TreeFrog Therapeutics headquartered?
TreeFrog Therapeutics is based in Bordeaux, Aquitaine, France.
How many employees does TreeFrog Therapeutics have?
TreeFrog Therapeutics is in the 101-250 employee band.
How does TreeFrog Therapeutics' funding compare to other Biotechnology startups?
TreeFrog Therapeutics' latest round of $34.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's TreeFrog Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TreeFrog Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.